Form D · Pharmaceuticals
Pacylex Pharmaceuticals Inc.
Calgary, A0 · CIK 0001866841
Offering snapshot reported Apr 4, 2024 · SEC filing
- Reported sold
- $75K Offering amount: $75K
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 21, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 4, 2024 | Initial | $75,000 | No comparison | 3 | SEC filing |
| Jun 14, 2021 | Initial | $7,184,198 | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Security to be acquired
- Exemptions
- 06c
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-509694
This filing covers, in part, the sale of common shares issued as a result of the conversion of convertible notes.
Source: Form D, filed Apr 4, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Luc G. Berthiaume | Director |
| Ajit Gill | Director |
| Ryan Heit | Executive |
| Mark Huson | Director |
| Cindy Jacobs | Director |
| John Mackey | Director |
| Nola Masterson | Director |
| Michael Weickert | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
400 3rd Avenue Sw Suite 3700
Calgary, A0, T2P 4H2
Calgary, A0, T2P 4H2